Companies such as GlaxoSmithKline, AstraZeneca, Amgen, AbbVie, Lilly, Novartis, and others are investing heavily in computational tools to benchmark and boost the predictability power in their biologics pipeline. These organizations are seeking innovative partners in AI-driven drug discovery, antibody modelling, biophysical characterization, developability profiling, and high-throughput screening solution providers to accelerate R&D timelines and de-risk decision making.

Join us and build meaningful connections with computational drug development decision makers, hoping to pave new ways to collaborate and accelerate biologics discovery and development across their portfolios.

Collaborate with us to create a bespoke partnership package that aligns with your preferences as solution providers. We are keen to ensure you connect with the individuals you want, in the manner that suits you best. Whether through presentations, one-on-one meetings, booths, or private dinners, take advantage of this opportunity to spotlight your solutions and achieve your 2025 business development objectives.